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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to various 
microorganisms and reduction of gastro-intestinal discomfort (ID 1030, 
2956, 2958, 2961, 2963, 2966, 2970), decreasing potentially pathogenic 
gastro-intestinal microorganisms (ID 1030, 2956, 2958, 2961, 2963, 2966, 
2970), improved lactose digestion (ID 1030, 2956, 2958, 2961, 2963, 2966, 
2970), “intestinal flora/digestive health” (ID 4231), defence against vaginal 
pathogens (ID 2950, 2957, 2967) and increasing IL-10 production and/or 
enhancing the activity of natural killer cells (ID 2960, 2962, 2971) (further 
assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006
1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies 
(NDA) was asked to provide a scientific opinion on health claims pursuant to Article 13 of Regulation (EC) No 
1924/2006  in  the  framework  of  further  assessment  related  to  various  microorganisms  and  reduction  of 
gastro-intestinal  discomfort,  decreasing  potentially  pathogenic  gastro-intestinal  microorganisms,  improved 
lactose digestion, “intestinal  flora/digestive  health”, defence against vaginal pathogens and increasing IL-10 
production and/or enhancing the activity of natural killer cells. The food constituents Lactobacillus crispatus 
BCCM/LMG  P-17631,  Lactobacillus  gasseri  BCCM/LMG  P-17632,  Lactobacillus  gasseri  BCCM/LMG P-
18137,  Lactobacillus  paracasei  CNCM  I-1687,  Lactobacillus  paracasei  CNCM  I-1688,  Lactobacillus 
plantarum BCCM/LMG P-17630, Lactobacillus salivarius CNCM I-1794 and a combination of Bifidobacterium 
animalis ssp. lactis Bf-6 and Lactobacillus johnsonii La-1 (ACD-1)(CLbA22) are sufficiently characterised. The 
evidence  provided  did  not  establish  that  the  proposed  claimed  effect,  increasing  IL-10  production  and/or 
enhancing the activity of natural killer cells, is a beneficial physiological effect. The claimed effect “intestinal 
flora/digestive health” is general and non-specific, and does not refer to any specific health claim as required by 
Regulation (EC) No 1924/2006. The references provided in relation to the claims evaluated in this opinion 
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included studies which assessed the effects of food constituents other than the food constituents which are the 
subject of the claims and/or investigated health outcomes unrelated to the claimed effects. No human studies 
which investigated the effects of the food constituents on appropriate measures of the claimed effects were 
provided. On the basis of the data presented, the Panel concludes that a cause and effect relationship has not been 
established between the consumption of the food constituents and the claimed effects evaluated in this opinion.  
© European Food Safety Authority, 2012 
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to provide a scientific opinion on a list of health claims pursuant to Article 
13 of Regulation (EC) No 1924/2006. The Commission has agreed with EU Member States that a 
certain number of Article 13 health claims would be eligible for further assessment by EFSA in order 
to be able to take a final decision on whether or not to include these claims in the list of permitted 
health  claims.  This  opinion  addresses  the  scientific  substantiation  of  health  claims  in  relation  to 
various  microorganisms  and  reduction  of  gastro-intestinal  discomfort,  decreasing  potentially 
pathogenic  gastro-intestinal  microorganisms,  improved  lactose  digestion,  “intestinal  flora/digestive 
health”,  defence  against  vaginal  pathogens  and  increasing  IL-10  production  and/or  enhancing  the 
activity of natural killer cells. The scientific substantiation is based on the information provided by the 
competent Authority of Italy for further assessment of these claims. 
The following food constituents are sufficiently characterised: 
Lactobacillus crispatus BCCM/LMG P-17631 (ID1030, 2950), 
Lactobacillus gasseri BCCM/LMG P-17632 (ID 2956), 
Lactobacillus gasseri BCCM/LMG P-18137 (ID 2957, 2958),  
Lactobacillus paracasei CNCM I-1687 (ID 2960, 2961),  
Lactobacillus paracasei CNCM I-1688 (ID 2962, 2963),  
Lactobacillus plantarum BCCM/LMG P-17630 (ID 2966, 2967),  
Lactobacillus salivarius CNCM I-1794 (ID 2970, 2971),  
a combination of Bifidobacterium animalis ssp. lactis Bf-6 and Lactobacillus johnsonii La-1 
(ACD-1)(CLbA22) (ID 4231). 
Reduction of gastro-intestinal discomfort (ID 1030, 2956, 2958, 2961, 2963, 2966, 2970) 
The claimed effect which is proposed for further assessment relates to reduction of gastro-intestinal 
discomfort. The proposed target population is the general population. Reduction of gastro-intestinal 
discomfort is a beneficial physiological effect. 
No  human  intervention  studies  were  provided  from  which  conclusions  could  be  drawn  for  the 
scientific substantiation of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of the food constituents which are the subject of the claims 
and reduction of gastro-intestinal discomfort.  
Decreasing potentially pathogenic gastro-intestinal microorganisms (ID 1030, 2956, 2958, 2961, 
2963, 2966, 2970) 
The  claimed  effect  which  is  proposed  for  further  assessment  relates  to  a  decrease  in  potentially 
pathogenic gastro-intestinal microorganisms. The proposed target population is the general population. 
Decreasing  potentially  pathogenic  gastro-intestinal  microorganisms  might  be  a  beneficial 
physiological effect. 
No  human  intervention  studies  were  provided  from  which  conclusions  could  be  drawn  for  the 
scientific substantiation of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of the food constituents which are the subject of the claims 
and decreasing potentially pathogenic gastro-intestinal microorganisms.  Health claims related to various microorganisms (further assessment) 
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Improved lactose digestion (ID 1030, 2956, 2958, 2961, 2963, 2966, 2970) 
The claimed effect which is proposed for further assessment relates to improved lactose digestion. 
Improved  lactose  digestion  is  a  beneficial  physiological  effect  for  individuals  with  lactose 
maldigestion. 
No  human  intervention  studies  were  provided  from  which  conclusions  could  be  drawn  for  the 
scientific substantiation of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of the food constituents which are the subject of the claims 
and improved lactose digestion.  
“Intestinal flora/digestive health” (ID 4231) 
No health relationship is proposed for further assessment. The health relationship submitted in the 
consolidated list for the initial assessment was “intestinal flora/digestive health”. The target population 
is assumed to be the general population.  
On the basis of the data presented, the Panel considers that the claimed effect is general and non-
specific, and does not refer to any specific health claim as required by Regulation (EC) No 1924/2006. 
Defence against vaginal pathogens (ID 2950, 2957, 2967) 
The  claimed  effect  which  is  proposed  for  further  assessment  relates  to  defence  against  vaginal 
pathogens by increasing the number of lactobacilli and/or decreasing potentially pathogenic bacteria. 
The target population is the female population. Defence against vaginal pathogens is a beneficial 
physiological effect. 
No  human  intervention  studies  were  provided  from  which  conclusions  could  be  drawn  for  the 
scientific substantiation of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of the food constituents which are the subject of the claims 
and defence against vaginal pathogens. 
Increasing IL-10 production and/or enhancing the activity of natural killer cells (ID 2960, 2962, 
2971) 
The claimed effect which is proposed for further assessment relates to increasing IL-10 production 
and/or enhancing the activity of natural killer cells. The proposed target population is the general 
population. The Panel notes that increasing IL-10 production and/or enhancing the activity of natural 
killer  cells  is  not  a  beneficial  physiological  effect  per  se,  but  needs  to  be  linked  to  a  beneficial 
physiological or clinical outcome.  
The Panel considers that the evidence provided did not establish that increasing IL-10 production 
and/or enhancing the activity of natural killer cells is a beneficial physiological effect. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of the food constituents which are the subject of the health 
claims  and  a  beneficial  physiological  effect  related  to  an  increase  in  IL-10  production  and/or  an 
enhancement of the lytic activity of natural killer cells. Health claims related to various microorganisms (further assessment) 
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INTRODUCTION 
The Commission has agreed with EU Member States that a certain number of Article 13 health claims 
would be eligible for further assessment by EFSA in order to be able to take a final decision on 
whether or not to include these claims in the list of permitted health claims. These claims include 
already assessed claims related to micro-organisms which the Panel considered to be not sufficiently 
characterised and claims for which the NDA Panel concluded that there was insufficient evidence to 
establish a cause and effect relationship between the consumption of the food and the claimed effect. 
Following an opinion of the NDA Panel pursuant to Article 13 of Regulation (EC) No 1924/2006
4 in 
which the Panel concluded that the data available were not sufficient to  characterise Lactobacillus 
crispatus P-17631 (ID 1030, 2950), Lactobacillus gasseri P-17632 (ID 2956), Lactobacillus gasseri P-
18137 (ID 2957, 2958), Lactobacillus paracasei I-1687 (ID 2960, 2961), Lactobacillus paracasei 
I-1688 (ID 2962, 2963), Lactobacillus plantarum P-17630 (ID 2966, 2967), Lactobacillus salivarius 
I-1794 (ID 2970, 2971) and a combination of Bifidobacterium animalis ssp. lactis Bf-6/Bif-6/CB111 
and  Lactobacillus  johnsonii  La-1/ACD-1/CLbA22  (A/B-61)  (ID  4231)  (EFSA  Panel  on  Dietetic 
Products Nutrition and Allergies (NDA), 2009, 2010), EFSA received additional information from the 
competent Authority of Italy for further assessment of these claims. The information provided in the 
framework of further assessment for the health claims which are the subject of this opinion is tabulated 
in Appendix C. 
ASSESSMENT 
1.  Characterisation of the food/constituent 
1.1.  Lactobacillus crispatus BCCM/LMG P-17631 (ID1030, 2950) 
The  food  constituent  that  is  the  subject  of  the  proposed  health  claims  is  Lactobacillus  crispatus 
BCCM/LMG P-17631. 
For L. crispatus BCCM/LMG P-17631, a culture collection number from the Belgian Co-ordinated 
Collections  of  Microorganisms  (BCCM/LMG  P-17631)  was  provided.  The  BCCM/LMG  is  an 
internationally  recognised  culture  collection  which  has  the  status  of  an  International  Depositary 
Authority under the Budapest Treaty. In the LMG, cultures can be deposited in a restricted-access 
collection for safe deposit or for patent purposes. Data on the identification and characterisation of 
L. crispatus BCCM/LMG P-17631 at species and strain level, by different phenotypic (carbohydrate 
fermentation profiles, PAGE) and genotypic (16S rRNA gene sequence analyses, plasmidic profile, 
ARDRA, Rep-PCR, AFLP) methods, were provided in the applications for further assessment and in 
the accompanying references (AAT, 2011a, unpublished, 2011b, unpublished; BCCM/LMG, 1997, 
unpublished; Dondi and Morelli, 1999, 2002; Morelli, 1997, unpublished). 
The  Panel  considers  that  the  food  constituent  that  is  the  subject  of  the  proposed  health  claims, 
L. crispatus BCCM/LMG P-17631, is sufficiently characterised. 
1.2.  Lactobacillus gasseri BCCM/LMG P-17632 (ID 2956) 
The  food  constituent  that  is  the  subject  of  the  proposed  health  claims  is  Lactobacillus  gasseri 
BCCM/LMG P-17632. 
For L. gasseri BCCM/LMG P-17632, a culture collection number from the BCCM/LMG, P-17632, 
was provided. Data on the identification and characterisation of L. gasseri BCCM/LMG P-17632 at 
species  and  strain  level,  by  different  phenotypic  (carbohydrate  fermentation  profiles,  PAGE)  and 
genotypic (16S rRNA gene sequence analyses, ARDRA, Rep-PCR, PFGE) methods, were provided in 
                                                       
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  Health claims related to various microorganisms (further assessment) 
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the application for further assessment and in the accompanying references (AAT, 2011c, unpublished; 
BCCM/LMG, 1997, unpublished; Dondi and Morelli, 1999, 2002; Morelli, 1997, unpublished).  
The  Panel  considers  that  the  food  constituent  that  is  the  subject  of  the  proposed  health  claims, 
L. gasseri BCCM/LMG P-17632, is sufficiently characterised. 
1.3.  Lactobacillus gasseri BCCM/LMG P-18137 (ID 2957, 2958) 
The  food  constituent  that  is  the  subject  of  the  proposed  health  claims  is  Lactobacillus  gasseri 
BCCM/LMG P-18137. 
For L. gasseri BCCM/LMG P-18137, a culture collection number from the BCCM/LMG, P-18137, 
was provided. Data on the identification and characterisation of L. gasseri BCCM/LMG P-18137 at 
species and strain level, by different phenotypic (carbohydrate fermentation profiles) and genotypic 
(16S  rRNA  gene  sequence  analyses,  ARDRA,  Rep-PCR,  PFGE)  methods,  were  provided  in  the 
applications for further assessment and in the accompanying references (AAT, 2011d, unpublished; 
BCCM/LMG, 1998, unpublished; Dondi and Morelli, 1999, 2002).  
The  Panel  considers  that  the  food  constituent  that  is  the  subject  of  the  proposed  health  claims, 
L. gasseri BCCM/LMG P-18137, is sufficiently characterised. 
1.4.  Lactobacillus paracasei CNCM I-1687 (ID 2960, 2961) 
The  food  constituent that is  the  subject of the  proposed  health  claims  is  Lactobacillus  paracasei 
CNCM I-1687. 
For L. paracasei CNCM I-1687, a culture collection number from the French National Collection of 
Cultures of Microorganisms (CNCM I-1687) was provided. The CNCM is a restricted-access non-
public collection which has the status of an International Depositary Authority under the Budapest 
Treaty. Data on the identification and characterisation of L. paracasei CNCM I-1687 at species and 
strain level, by different phenotypic (carbohydrate fermentation profiles) and genotypic (16S rRNA 
gene sequence analyses, plasmidic profile, ARDRA, Rep-PCR, AFLP) methods, were provided in the 
applications for further assessment and in the accompanying references (AAT, 2011b, unpublished, 
2011e, unpublished; Morelli, 1996, unpublished; Morelli, 1997, unpublished).  
The  Panel  considers  that  the  food  constituent  that  is  the  subject  of  the  proposed  health  claims, 
L. paracasei CNCM I-1687, is sufficiently characterised. 
1.5.  Lactobacillus paracasei CNCM I-1688 (ID 2962, 2963) 
The  food  constituent that is  the  subject of the  proposed  health  claims  is  Lactobacillus  paracasei 
CNCM I-1688. 
For L. paracasei CNCM I-1688, a culture collection number from the CNCM, I-1688, was provided. 
Data on the identification and characterisation of L. paracasei CNCM I-1688 at species and strain 
level, by different phenotypic (carbohydrate fermentation profiles) and genotypic (16S rRNA gene 
sequence analyses, plasmidic profile, ARDRA, RAPD, Rep-PCR, PFGE) methods, were provided in 
the applications for further assessment and in the accompanying references (AAT, 2011f, unpublished; 
Bonetti et al., 2002; Morelli, 1996, unpublished; Morelli, 1997, unpublished).  
The  Panel  considers  that  the  food  constituent  that  is  the  subject  of  the  proposed  health  claims, 
L. paracasei CNCM I-1688, is sufficiently characterised. Health claims related to various microorganisms (further assessment) 
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1.6.  Lactobacillus plantarum BCCM/LMG P-17630 (ID 2966, 2967) 
The food constituent that is the subject of the  proposed health claims is Lactobacillus plantarum 
BCCM/LMG P-17630. 
For L. plantarum BCCM/LMG P-17630, a culture collection number from the BCCM/LMG, P-17630, 
was provided. Data on the identification and characterisation of L. plantarum BCCM/LMG P-17630 at 
species  and  strain  level,  by  different  phenotypic  (carbohydrate  fermentation  profile,  antibiotic 
resistance pattern, PAGE) and genotypic (16S rRNA gene sequence analyses, ARDRA, Rep-PCR, 
PFGE, genome sequencing) methods, were provided in the applications and in the accompanying 
references (AAT, 2011g, unpublished; BCCM/LMG, 1997, unpublished; Dho et al., 2003; Dondi, 
2000;  Escorsell,  2007;  Morelli,  1997,  unpublished;  Semiautomatic  Genome  Annotation,  2010, 
unpublished).  
The  Panel  considers  that  the  food  constituent  that  is  the  subject  of  the  proposed  health  claims, 
L. plantarum BCCM/LMG P-17630, is sufficiently characterised. 
1.7.  Lactobacillus salivarius CNCM I-1794 (ID 2970, 2971) 
The  food  constituent that is  the  subject of the  proposed  health  claims  is  Lactobacillus  salivarius 
CNCM I-1794. 
For L. salivarius CNCM I-1794, a culture collection number from the CNCM, I-1794, was provided. 
Data on the identification and characterisation of L. salivarius CNCM I-1794 at species and strain 
level, by different phenotypic (carbohydrate fermentation profiles, antibiotic resistance pattern) and 
genotypic (16S rRNA gene sequence analyses, plasmidic profile, ARDRA, RAPD, Rep-PCR, PFGE) 
methods, were provided in the applications for further assessment and in the accompanying references 
(AAT, 2011h, unpublished; Bonetti et al., 2002; Morelli, 1997, unpublished; Pedraglio, 2004). 
The  Panel  considers  that  the  food  constituent  that  is  the  subject  of  the  proposed  health  claims, 
L. salivarius CNCM I-1794, is sufficiently characterised. 
1.8.  Α combination of Bifidobacterium animalis ssp. lactis Bf-6 and Lactobacillus johnsonii 
La-1 (ACD-1)(CLbA22) (ID 4231) 
The  food  constituent  that  is  the  subject  of  the  proposed  health  claim  is  a  combination  of 
Bifidobacterium animalis ssp. lactis Bf-6 and Lactobacillus johnsonii La-1 (ACD-1)(CLbA22). 
The strain B. animalis ssp. lactis Bf-6 is also known as Bifidobacterium animalis ssp. lactis CB111. A 
culture  collection  number  from  the  BCCM/LMG,  LMG  24384,  was  provided.  Data  on  the 
identification  and  characterisation  of  B.  animalis  ssp.  lactis  Bf-6  at  species  and  strain  level,  by 
different  genotypic  (16S  rRNA  gene  sequence  analysis,  RAPD,  Rep-PCR,  genome  sequencing) 
methods, were provided in the application for further assessment and in the accompanying references 
(Cargill, 2011a, unpublished; Ehrmann, 2006, unpublished; Integrated Genomics, 2011, unpublished; 
MIDI Labs, 2011a, unpublished, 2011b, unpublished). The Panel considers that B. animalis ssp. lactis 
Bf-6 is sufficient characterised. 
For L. johnsonii La-1 (ACD-1)(CLbA22), a culture collection number from the BCCM/LMG, LMG 
24394, was provided. Data on  the identification and characterisation of L. johnsonii  La-1 (ACD-
1)(CLbA22) at species and strain level, by different genotypic (16S rRNA gene sequence analysis, 
RAPD,  Rep-PCR)  methods,  were  provided  in  the  application  for  further  assessment  and  in  the 
accompanying  references  (Cargill,  2011b,  unpublished,  2011c,  unpublished;  Ehrmann,  2006, 
unpublished).  The  Panel  considers  that  L.  johnsonii  La-1  (ACD-1)(CLbA22)  is  sufficiently 
characterised. Health claims related to various microorganisms (further assessment) 
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The Panel considers that the food constituent that is the subject of the proposed health claims, a 
combination of B. animalis ssp. lactis Bf-6 and L. johnsonii La-1 (ACD-1)(CLbA22), is sufficiently 
characterised. 
2.  Relevance of the claimed effect to human health 
2.1.  Reduction of gastro-intestinal discomfort (ID 1030, 2956, 2958, 2961, 2963, 2966, 2970) 
The  claimed  effect  which  is  proposed for  further  assessment  is:  “Is  a  probiotic;  Contributes to a 
healthy  digestive  system  by  supporting  the  gut  flora  through  an  increased  number  of  positive 
lactobacillus in the intestine; useful to maintain a healthy intestinal flora by adhering to the mucosa; 
Improves intestinal barrier function by competing (steric encumbrance) against pathogens; Reduces 
gastro-intestinal  discomfort;  Necessary  to  maintain  a  healthy  digestive  system  by  production  of 
specific enzymes (e.g. beta-galactosidase).” The proposed target population is the general population. 
The Panel considers that reduction of gastro-intestinal discomfort is a beneficial physiological effect. 
2.2.  Decreasing  potentially  pathogenic  gastro-intestinal  microorganisms  (ID  1030,  2956, 
2958, 2961, 2963, 2966, 2970) 
The  claimed  effect  which  is  proposed for  further  assessment  is:  “Is  a  probiotic;  Contributes to a 
healthy  digestive  system  by  supporting  the  gut  flora  through  an  increased  number  of  positive 
lactobacillus in the intestine; useful to maintain a healthy intestinal flora by adhering to the mucosa; 
Improves intestinal barrier function by competing (steric encumbrance) against pathogens; Reduces 
gastro-intestinal  discomfort;  Necessary  to  maintain  a  healthy  digestive  system  by  production  of 
specific  enzymes  (e.g.  beta-galactosidase).”  The  proposed  target  population  is  the  general  adult 
population. 
The Panel notes that it is not possible to define the exact number of the different microbial groups 
which  constitute  a  normal  microbiota.  Increasing  the  number  of  any  groups  of  microorganisms, 
including lactobacilli, is not in itself considered to be a beneficial physiological effect.  
The Panel assumes that the claimed effect refers to decreasing potentially pathogenic gastro-intestinal 
microorganisms. The  Panel  considers  that  decreasing  potentially  pathogenic  gastro-intestinal 
microorganisms might be a beneficial physiological effect. 
2.3.  Improved lactose digestion (ID 1030, 2956, 2958, 2961, 2963, 2966, 2970) 
The  claimed  effect  which  is  proposed for  further  assessment  is:  “Is  a  probiotic;  Contributes to a 
healthy  digestive  system  by  supporting  the  gut  flora  through  an  increased  number  of  positive 
lactobacillus in the intestine; useful to maintain a healthy intestinal flora by adhering to the mucosa; 
Improves intestinal barrier function by competing (steric encumbrance) against pathogens; Reduces 
gastro-intestinal  discomfort;  Necessary  to  maintain  a  healthy  digestive  system  by  production  of 
specific enzymes (e.g. beta-galactosidase)”. The proposed target population is the general population. 
The Panel assumes that the claimed effect refers to improved lactose digestion, and that the target 
population  is  individuals  with  lactose  maldigestion.  Lactose  maldigestion  is  a  common  condition 
caused by reduced levels of intestinal lactase.  
The Panel considers that improved lactose digestion is a beneficial physiological effect for individuals 
with lactose maldigestion. 
2.4.  “Intestinal flora/digestive health” (ID 4231) 
In the application submitted for further assessment of the health claim, no health relationship, wording 
or references for the substantiation of the health effect have been provided. The health relationship Health claims related to various microorganisms (further assessment) 
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submitted in the consolidated list for the initial assessment was “intestinal flora/digestive health”. The 
Panel assumes that the target population is the general population.  
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
2.5.  Defence against vaginal pathogens (ID 2950, 2957, 2967) 
The  claimed  effect  which  is  proposed  for  further  assessment  is:  “Helps  in  maintaining  balanced 
vaginal flora and pH; Contributes to a healthy colonization of the lactobacilli on the vagina; Helps to 
redress the healthy balanced vaginal microflora during and after the treatment of vaginal disorders”. 
The proposed target population is the female population. 
The Panel notes that the claimed effect refers to defence against vaginal pathogens by increasing the 
number of lactobacilli and/or decreasing potentially pathogenic bacteria. 
Unlike any other anatomical site of the body, most vaginal vaults are dominated by one or more 
species of Lactobacillus. In over 70 % of women, the vaginal microbiota is dominated by lactobacilli 
(> 50 %) (Ling et al., 2010; Ravel et al., 2011; Yamamoto et al., 2009). This microbiota is different 
from the more complex gut microbiota, where lactobacilli represent less than 3 % of the bacterial 
population  (Franks  et  al.,  1998;  Lay  et  al.,  2005;  Sghir  et  al.,  2000).  The  diagnosis  of  bacterial 
vaginosis (BV) can be based for example on the Nugent score (microscopic examination of Gram 
stained smear or vaginal discharge for bacteria and „clue‟ cells). The Panel notes that appropriate 
outcome measures of the claimed effect include assessment of changes in the Nugent scores. Nugent 
scores are estimated by measuring the relative amounts of lactobacilli and bacterial pathogens present 
in  the  vagina.  A  Nugent  score  of  0-3  is  classified  as  normal  (lactobacilli  are  present,  but  not 
Gardnerella/Bacteroides or curved Gram-negative bacilli), a score of 4-6 as intermediate (colonisation 
by Gardnerella/Bacteroides and curved Gram-variable rods [Mobiluncus]), and a score of 7-10 is 
indicative f BV (with domination of Gardnerella/Bacteroides or curved Gram-negative bacilli and 
absence of lactobacilli). 
The Panel considers that defence against vaginal pathogens is a beneficial physiological effect. 
2.6.  Increasing  IL-10  production  and/or  enhancing  the  activity  of  natural  killer  cells 
(ID 2960, 2962, 2971) 
The claimed effects which are proposed for further assessment are: “Supports your natural (immune) 
defence system by increasing the IL-10 production and enhancing NK cell activity in peripheral blood 
mononuclear cells (PBMC); Necessary to maintain the natural defences/helps to maintain a balanced 
immune system (increasing the IL-10 production and enhancing NK cell activity)”, and “Supports 
your  natural  (immune)  defence  system  by  increasing  the  IL-10  production  in  peripheral  blood 
mononuclear cells (PBMC); Necessary to maintain the natural defences/helps to maintain a balanced 
immune system (increasing the IL-10 production)”. The proposed target population is the general 
population. 
The Panel notes that the claimed effect “supports your natural (immune) defence system /necessary to 
maintain  the  natural  defences  /helps  to  maintain  a  balanced  immune  system”  is  not  sufficiently 
defined, and assumes that the claimed effect relates to increasing IL-10 production by peripheral blood 
mononuclear cells and/or enhancing the lytic activity of natural killer cells. 
The  Panel  notes  that  increasing  IL-10  production  by  peripheral  blood  mononuclear  cells  and/or 
enhancing the lytic activity of natural killer cells is not a beneficial physiological effect per se, but 
needs to be linked to a beneficial physiological or clinical outcome. 
Most of the references provided in relation to these claims were on methodologies for bacterial strain 
identification;  in  vitro  studies  on  immunomodulatory  properties  (i.e.  lymphocyte  proliferation, Health claims related to various microorganisms (further assessment) 
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phenotype of the lymphocytic subpopulations, cytokine production) (Castellazzi, 2007a, unpublished; 
Castellazzi et al., 2007b; Castellazzi, 2007c, unpublished); and a patent (Dondi and Malfa, 2007) 
which reported the results of the in vitro study by Castellazi et al. (2007a, unpublished).   
In relation to ID 2962 and 2971, two references reported on the same single-arm (no control group) 
human intervention study (Castellazzi, 2007a, unpublished; Valsecchi et al., 2008) which investigated 
the effects of two strains in combination, while the single strains are the subject of the claims, on 
allergy  symptoms  (atopic dermatitis,  rhino-conjunctivitis,  urticaria,  contact  dermatitis,  oral  allergy 
syndrome  and  food  allergies)  and  immunological  parameters  (i.e.  lymphocyte  population,  natural 
killer activity and cytokine production) in 20 children with atopic disorders. The Panel notes that this 
single-arm study was not controlled and investigated a combination of strains rather than the single 
strains which are the subject of the claim, and considers that no conclusions can be drawn from this 
study for the scientific substantiation of the claim. 
The Panel considers that the evidence provided does not establish that increasing IL-10 production by 
peripheral  blood  mononuclear  cells  and/or  enhancing  the  lytic  activity  of  natural  killer  cells  is  a 
beneficial physiological effect.  
The  Panel  concludes  that  a  cause  and  effect  relationship  has  not  been  established  between  the 
consumption of the food constituents which are the subject of the health claims and a beneficial 
physiological effect related to an increase in IL-10 production and/or an enhancement of the lytic 
activity of natural killer cells.  
3.  Scientific substantiation of the claimed effect 
3.1.  Reduction of gastro-intestinal discomfort (ID 1030, 2956, 2958, 2961, 2963, 2966, 2970) 
Most of the references provided in relation to these claims were on methodologies for bacterial strain 
identification (Jensen et al., 1993; Ventura et al., 2000), abstracts from a congress on the isolation of 
specific bacterial strains (Pietronave et al., 2003) or on the properties of a strain (Pietronave et al., 
2004), which were unrelated to the claimed effect.  
Patents on methods for the selection of Lactobacillus strains (e.g. L. crispatus P-17631, L. gasseri 
P-17632 and L. gasseri P-18137) with antimicrobial activity (Dondi and Morelli, 1999, 2002); patents 
on methods for selection of Lactobacillus strains (e.g. L. paracasei CNCM I-1687 and L. paracasei 
CNCM I-1688) indicated to be useful for the treatment of various disorders of the gastro-intestinal 
tract because of their capability to produce lactic acid (Pedraglio, 2004), or with high ability to adhere 
to human mucosa (e.g. L. plantarum LMG P-17630) (Dondi, 2000), or patents for the use of two 
bacterial  strains  (L.  gasseri  P-17632  and  L.  salivarius  CNCM  I-1794)  against  Candida  albicans 
(Dondi, 2004, 2007), were also provided. One human intervention study on the viability of the strains 
through the human intestinal tract (Bonetti et al., 2002) and one in vitro study on the properties of the 
bacterial strain (i.e. growth at different temperatures and pH levels (Dho et al., 2003)) were also 
provided. The Panel notes that these references were unrelated to the claimed effect, and considers that 
no conclusions can be drawn from these references for the scientific substantiation of the claim. 
The Panel notes that no human studies were provided from which conclusions could be drawn for the 
scientific substantiation of the claims evaluated in this section. 
The  Panel  concludes  that  a  cause  and  effect  relationship  has  not  been  established  between  the 
consumption of the food constituents which are the subject of the claims evaluated in this section and 
reduction of gastro-intestinal discomfort.  Health claims related to various microorganisms (further assessment) 
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3.2.  Decreasing  potentially  pathogenic  gastro-intestinal  microorganisms  (ID  1030,  2956, 
2958, 2961, 2963, 2966, 2970) 
Most of the references provided in relation to these claims were on methodologies for bacterial strain 
identification (Jensen et al., 1993; Ventura et al., 2000), abstracts from a congress on the isolation of 
specific bacterial strains (Pietronave et al., 2003) or on the properties of a strain (Pietronave et al., 
2004), which were unrelated to the claimed effect.  
Patents on methods for the selection of Lactobacillus strains (e.g. L. crispatus P-17631, L. gasseri 
P-17632 and L. gasseri P-18137) with antimicrobial activity, in which the in vitro inhibitory activity 
of  the  strain  that  is  the  subject  of  the  claim  against  Candida  albicans  and  Streptococcus  β-
haemolyticus  was  mentioned  (Dondi  and  Morelli,  1999,  2002)  were  provided.  Also  patents  on 
methods for the selection of Lactobacillus strains (e.g. L. paracasei CNCM I-1687 and L. paracasei 
CNCM I-1688) indicated to be useful for the treatment of various disorders of the gastro-intestinal 
tract because of their capability to produce lactic acid (Pedraglio, 2004)), or with high ability to adhere 
to human mucosa (e.g. L. plantarum LMG P-17630) (Dondi, 2000) were provided. Two patents for the 
use of L. gasseri P-17632 and L. salivarius CNCM I-1794, alone or in combination, against Candida 
albicans (Dondi, 2004, 2007) were also provided. The Panel notes that no primary data were provided 
in these patents that could be used for the substantiation of the claim. The Panel considers that no 
conclusions can be drawn from these references for the scientific substantiation of the claim.   
One human intervention study on the viability of the strains through the human intestinal tract (Bonetti 
et al., 2002) and one in vitro study on the properties of the bacterial strain (i.e. growth at different 
temperatures and pH levels (Dho et al., 2003)) were also provided. The Panel notes that these studies 
did not address outcome measures related to the claimed effect, and considers that no conclusions can 
be drawn from these studies for the scientific substantiation of the claim. 
The Panel notes that no human studies were provided from which conclusions could be drawn for the 
scientific substantiation of the claims evaluated in this section. 
The  Panel  concludes  that  a  cause  and  effect  relationship  has  not  been  established  between  the 
consumption of the food constituents which are the subject of the claims evaluated in this section and 
decreasing potentially pathogenic gastro-intestinal microorganisms.  
3.3.  Improved lactose digestion (ID 1030, 2956, 2958, 2961, 2963, 2966, 2970) 
Patents on methods for the selection of Lactobacillus strains (e.g. L. crispatus P-17631, L. gasseri 
P-17632 and L. gasseri P-18137) with antimicrobial activity (Dondi and Morelli, 1999, 2002); patents 
on methods for selection of lactobacilli strains (e.g. L. paracasei CNCM I-1687 and L. paracasei 
CNCM I-1688) indicated to be useful for the treatment of various disorders of the gastro-intestinal 
tract because of their capability to produce lactic acid (Pedraglio, 2004), or with high ability to adhere 
to human mucosa (e.g. L. plantarum LMG P-17630) (Dondi, 2000), or patents for the use of two 
bacterial strains (e.g. L. gasseri P-17632 and L. salivarius CNCM I-1794) against Candida albicans 
(Dondi, 2004, 2007), were also provided. One human intervention study on the viability of the strains 
through the human intestinal tract (Bonetti et al., 2002) and one in vitro study on the properties of the 
bacterial strain (i.e. growth at different temperatures and pH levels  (Dho et al., 2003)) were also 
provided. The Panel notes that these references were unrelated to the claimed effect, and considers that 
no conclusions can be drawn from these references for the scientific substantiation of the claim. 
The Panel notes that no human studies were provided from which conclusions could be drawn for the 
scientific substantiation of the claims evaluated in this section. 
The  Panel  concludes  that  a  cause  and  effect  relationship  has  not  been  established  between  the 
consumption of the food constituents which are the subject of the claims evaluated in this section and 
improved lactose digestion.  Health claims related to various microorganisms (further assessment) 
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3.4.  Defence against vaginal pathogens (ID 2950, 2957, 2967) 
Most of the references provided in relation to these claims were on methodologies for bacterial strain 
identification (Jensen et al., 1993; Ventura et al., 2000); an abstract from a congress on the isolation of 
specific bacterial strains (Pietronave et al., 2003); patents on methods for selection of Lactobacillus 
strains (e.g. L. plantarum LMG P-17630) with high ability to adhere to human mucosa (Dondi, 2000), 
in vitro studies which reported on properties of the strains (e.g. adherence to vaginal epithelial cells 
(Bonetti et al., 2003; Culici et al., 2004; Escorsell, 2007), or on viability at different pH (Morelli, 
2000)). The Panel notes that these references did not address outcome measures related to the claimed 
effect.  
Patents on methods for the selection of Lactobacillus strains (e.g. L. crispatus P-17631, L. gasseri 
P-17632 and L. gasseri P-18137) with antimicrobial activity, in which the in vitro inhibitory activity 
of  the  strain  that  is  the  subject  of  the  claim  against  Candida  albicans  and  Streptococcus  β-
haemolyticus was mentioned (Dondi and Morelli, 1999, 2002) were provided. Patents for the use of 
two  bacterial  strains  (i.e. L. gasseri  P-17632  and  L.  salivarius  CNCM  I-1794)  against  Candida 
albicans (Dondi, 2004, 2007), were also provided. The Panel notes that no primary data which could 
be  used  for  the  scientific  substantiation  of  the  claim  were  provided  in  these  patents.  The  Panel 
considers that no conclusions can be drawn from these references for the scientific substantiation of 
the claim 
A number of human intervention studies investigated the effects of the specific strain which is the 
subject of the claim when the strain was administrated intravaginally (Carriero et al., 2007; Escorsell, 
2007; Gianella, 2003; Nava et al., 2002). The Panel considers that studies made on substances which 
are not administered orally cannot be used to substantiate a claim on a food constituent.   
The Panel notes that no human studies were provided from which conclusions could be drawn for the 
scientific substantiation of the claims evaluated in this section. 
In relation to ID 2967, in vitro studies which addressed the effects of the strain that is the subject of 
the claim on the adhesion properties of Candida albicans to vaginal epithelia cells (Culici et al., 2004; 
Escorsell, 2007) were provided. The Panel considers that in the absence of evidence for an effect on 
defence against vaginal pathogens in humans, evidence provided in in vitro studies cannot be used 
alone for the scientific substantiation of a claim on defence against vaginal pathogens. 
The  Panel  concludes  that  a  cause  and  effect  relationship  has  not  been  established  between  the 
consumption of the food constituents which are the subject of the claims evaluated in this section and 
defence against vaginal pathogens. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
  The following food constituents are sufficiently characterised: 
Lactobacillus crispatus BCCM/LMG P-17631 (ID 1030, 2950), 
Lactobacillus gasseri BCCM/LMG P-17632 (ID 2956), 
Lactobacillus gasseri BCCM/LMG P-18137 (ID 2957, 2958),  
Lactobacillus paracasei CNCM I-1687 (ID 2960, 2961),  
Lactobacillus paracasei CNCM I-1688 (ID 2962, 2963),  
Lactobacillus plantarum BCCM/LMG P-17630 (ID 2966, 2967),  
Lactobacillus salivarius CNCM I-1794 (ID 2970, 2971),  Health claims related to various microorganisms (further assessment) 
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a combination of Bifidobacterium animalis ssp. lactis Bf-6 and Lactobacillus johnsonii La-1 
(ACD-1)(CLbA22) (ID 4231). 
Reduction of gastro-intestinal discomfort (ID 1030, 2956, 2958, 2961, 2963, 2966, 2970) 
  The claimed effect proposed for further assessment relates to reduction of gastro-intestinal 
discomfort.  The  proposed  target  population  is  the  general  population.  Reduction  of 
gastro-intestinal discomfort is a beneficial physiological effect. 
  A cause and effect relationship has not been established between the consumption of the food 
constituents which are the subject of the claims and reduction of gastro-intestinal discomfort.  
Decreasing potentially pathogenic gastro-intestinal microorganisms (ID 1030, 2956, 2958, 2961, 
2963, 2966, 2970) 
  The  claimed  effect  proposed  for  further  assessment  relates  to  decreasing  potentially 
pathogenic gastro-intestinal microorganisms. The proposed target population is the general 
population.  Decreasing  potentially  pathogenic  gastro-intestinal  microorganisms  might  be  a 
beneficial physiological effect. 
  A cause and effect relationship has not been established between the consumption of the food 
constituents which are the subject of the claims and decreasing potentially pathogenic gastro-
intestinal microorganisms.  
Improved lactose digestion (ID 1030, 2956, 2958, 2961, 2963, 2966, 2970) 
  The claimed  effect  proposed  for further  assessment  relates  to improved  lactose  digestion. 
Improved lactose digestion is a beneficial physiological effect for individuals with  lactose 
maldigestion. 
  A cause and effect relationship has not been established between the consumption of the food 
constituents which are the subject of the claims and improved lactose digestion.  
“Intestinal flora/digestive health” (ID 4231) 
  No health relationship is proposed for further assessment. The health relationship submitted in 
the  consolidated  list  for  the  initial  assessment  was  “intestinal  flora/digestive  health”.  The 
target population is assumed to be the general population.  
  The claimed effect is general and non-specific, and does not refer to any specific health claim 
as required by Regulation (EC) No 1924/2006. 
Defence against vaginal pathogens (ID 2950, 2957, 2967) 
  The  claimed  effect  proposed  for  further  assessment  relates  to  defence  against  vaginal 
pathogens by increasing the number of lactobacilli and/or decreasing potentially pathogenic 
bacteria. The target population is the female population. Defence against vaginal pathogens is 
a beneficial physiological effect. 
  A cause and effect relationship has not been established between the consumption of the food 
constituents which are the subject of the claims and defence against vaginal pathogens. Health claims related to various microorganisms (further assessment) 
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Increasing IL-10 production and/or enhancing the activity of natural killer cells (ID 2960, 2962, 
2971) 
  The claimed effect proposed for further assessment relates to increasing the IL-10 production 
and/or enhancing the activity of natural killer cells. The proposed target population is the 
general population. The evidence provided did not establish that increasing IL-10 production 
in peripheral blood mononuclear cells and/or enhancing the activity of natural killer cells is a 
beneficial physiological effect.  
  A cause and effect relationship has not been established between the consumption of the food 
constituents, which are the subject of the health claims, and a beneficial physiological effect 
related  to  an increase  in  IL-10  production and/or  an  enhancement  of  the  lytic  activity  of 
natural killer cells. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 for further assessment (No: 
EFSA-Q-2012-00160, EFSA-Q-2012-00183, EFSA-Q-2012-00186, EFSA-Q-2012-00187, EFSA-Q-
2012-00188,  EFSA-Q-2012-00189,  EFSA-Q-2012-00190,  EFSA-Q-2012-00191,  EFSA-Q-2012-
00192,  EFSA-Q-2012-00194,  EFSA-Q-2012-00195,  EFSA-Q-2012-00198,  EFSA-Q-2012-00199, 
EFSA-Q-2012-00215).  The  scientific  substantiation  is  based  on  the  information  provided  by  the 
competent  Authority  of  Italy  for  further  assessment  of  this  claim  (available  at: 
http://www.efsa.europa.eu/en/topics/topic/article13.htm). 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The  Regulation  1924/2006  on  nutrition  and  health  claims  made  on  foods
5  (hereinafter  "the 
Regulation") entered into force on 19
th January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a)  the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b)  psychological and behavioural functions; or 
c)  without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i)  based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January  2008  accompanied  by  the  conditions  applying  to  them  and  by  references to  the  relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
6  
Foods are commonly involved in many different functions
7 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be consi dered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to a 
single food is scientifically pertinent.  
It should also be considered if the information on the characteristics of the food contains aspect s 
pertinent to the beneficial effect.  
                                                       
5  OJ L12, 18/01/2007 
6  The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
7  The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   Health claims related to various microorganisms (further assessment) 
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SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific data, 
and by weighing the evidence, and shall demonstrate the extent to which: 
(a)  the claimed effect of the food is beneficial for human health, 
(b)  a cause and effect relationship is established between consumption of the food and the 
claimed  effect  in  humans  (such  as:  the  strength,  consistency,  specificity,  dose-
response, and biological plausibility of the relationship), 
(c)  the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d)  the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of the 
application for authorisation of health claims consistent criteria for the potential sources of scientific 
data. Such sources may not be available for all health claims. Nevertheless it will be relevant and 
important that EFSA comments on the availability and quality of such data in order to allow the 
regulator to judge and make a risk management decision about the acceptability of health claims 
included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not enough 
to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. Moreover, 
the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially affect identified 
functions in the body in a way which is relevant to health. Although an appreciation of the beneficial 
effect in relation to the nutritional status of the European population may be of interest, the presence or 
absence of the actual need for a nutrient or other substance with nutritional or physiological effect for 
that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic or 
cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of the 
body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function  of  the  joints"  may  not  sufficiently  do  so,  whereas  a  claim  such  as  "Substance  X  helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which specifies 
this by using the word "flexibility". Health claims related to various microorganisms (further assessment) 
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The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore be 
specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings should 
be avoided. To this end, wordings like "strengthens your natural defences" or "contain antioxidants" 
should be considered as well as "may" or "might" as opposed to words like "contributes", "aids" or 
"helps".  
In addition, for functions affected by a large number of dietary factors it should be considered whether 
wordings such as "indispensable", "necessary", "essential" and "important" reflects the strength of the 
scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
  Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
  Whether the beneficial effect of the food on the function is substantiated by generally accepted 
scientific evidence by taking into account the totality of the available scientific data, and by 
weighing the evidence. In this context EFSA is invited to comment on the nature and quality 
of the totality of the evidence provided according to consistent criteria. 
  The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the extent 
to which: 
  the claimed effect of the food in the identified function is beneficial. 
  a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
  where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
  the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. Health claims related to various microorganisms (further assessment) 
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  the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
  on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. Health claims related to various microorganisms (further assessment) 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of  the  food/food  constituent,  a  positive  assessment  of  its  safety,  nor  a  decision  on  whether  the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
 
 Health claims related to various microorganisms (further assessment) 
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APPENDIX C 
Table 1. Health claims related to various microorganisms, including conditions of use, as proposed in the framework of further assessment. 
ID  Food or Food constituent  Health Relationship  Proposed wording 
1030 
 
Lactobacillus crispatus 
BCCM/LMG P-17631  
Is a probiotic; Contributes to a healthy digestive system by supporting the gut flora 
through an increased number of positive lactobacillus in the intestine; useful to 
maintain a healthy intestinal flora by adhering to the mucosa; Improves intestinal 
barrier function by competing (steric encumbrance) against pathogens; Reduces 
gastro-intestinal discomfort; Necessary to maintain a healthy digestive system by 
production of specific enzymes (eg: beta-galactosidase). 
Is a probiotic that maintains the balance 
of healthy intestinal microflora and 
regulates intestinal functionality by 
replacing normal, natural microflora 
(especially after antibiotic/antimycotic 
treatment) which contributes to 
reducing gastro-intestinal discomfort 
which, for example, could be due to 
problems in lactose digestion.  
Conditions of use 
Being 'Generally Recognized as Safe' (GRAS) by the Food and Drug Administration, this health claim is destined for the general population.  
The advised condition of use of this constituent is of at least 1x10
8 ufc per day  
Since this product's release on the market, there have not been any reported cases of undesirable side effects due to this nutrient, however, italian national law 
imposes the use of these precautions on the product label: Do not exceed the indicated dosage; Keep out of reach of children under three years of age; The 
intake of this supplement is not meant as a substitute to a balanced diet and healthy lifestyle; This product does not substitute antibiotic or chemiotherapeutic 
therapy. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water or warm milk, and drink immediately. Should be consumed, 
preferably, on an empty stomach. 
2950  Food or Food constituent  Health Relationship  Proposed wording 
  Lactobacillus crispatus 
BCCM/LMG P-17631 
Helps in maintaining balanced vaginal flora and pH;  
Contributes to a healthy colonization of the lactobacilli on the vagina;  
Helps to redress the healthy balanced vaginal microflora during and after treatment 
of vaginal disorders. 
Is a probiotic that helps to maintain 
normal vaginal microflora and vaginal 
pH at physiological levels (acid pH) 
playing a part in the inhibition of 
pathogen growth, and also aids in 
replacing the vaginal ecosystem when 
modified after antibiotic/antimycotic 
treatment Health claims related to various microorganisms (further assessment) 
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Conditions of use 
This health claim is destined for the female population, due to the product's specific vaginal use. 
The advised condition of use of this constituent is of at least 1x108 ufc per day 
Since this product's release on the market, there have not been any reported cases of undesirable side effects due to this nutrient, however, italian national law 
imposes the use of these precautions on the product label: 
Do not exceed the indicated dosage; Keep out of reach of children under three years of age; The intake of this supplement is not meant as a substitute to a 
balanced diet and healthy lifestyle; This product does not substitute antibiotic or chemiotherapeutic therapy. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water or warm milk, and drink immediately. Should be consumed, 
preferably, on an empty stomach. 
2956  Food or Food constituent  Health Relationship  Proposed wording 
  Lactobacillus gasseri 
BCCM/LMG P-17632 
Is a probiotic;  
Contributes to a healthy digestive system by supporting the gut flora through an 
increased number of positive lactobacillus in the intestine;  
useful to maintain a healthy intestinal flora by adhering to the mucosa;  
Improves intestinal barrier function by competing 
(steric encumbrance) against pathogens;  
Reduces gastro-intestinal discomfort;  
Necessary to maintain a healthy digestive system by production of specific 
enzymes (eg: betagalactosidase). 
Is a probiotic that maintains the balance 
of healthy intestinal microflora and 
regulates intestinal functionality by 
replacing normal, natural microflora 
(especially after antibiotic/antimycotic 
treatment) which contributes to 
reducing gastro-intestinal discomfort 
which, for example, could be due to 
problems in lactose digestion. 
Conditions of use 
Being 'Generally Recognized as Safe' (GRAS) by the Food and Drug Administration, this health claim is destined for the general population. 
The advised condition of use of this constituent is of at least 1x10
8 ufc per day. 
Since this product's release on the market, there have not been any reported cases of undesirable side effects due to this nutrient, however, italian national law 
imposes the use of these precautions on the product label: Do not exceed the indicated dosage; Keep out of reach of children under three years of age; The 
intake of this supplement is not meant as a substitute to a balanced diet and healthy lifestyle; This product does not substitute antibiotic or chemiotherapeutic 
therapy. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water or warm milk, and drink immediately. Should be consumed, 
preferably, on an empty stomach. Health claims related to various microorganisms (further assessment) 
 
27  EFSA Journal 2012;10(8):2858 
2957  Food or Food constituent  Health Relationship  Proposed wording 
  Lactobacillus gasseri 
BCCM/LMG P-18137 
Helps in maintaining balanced vaginal flora and pH;  
Contributes to a healthy colonization of the lactobacilli on the vagina; Helps to 
redress the healthy balanced vaginal microflora during and after treatment of 
vaginal disorders. 
Is a probiotic that helps to maintain 
normal vaginal microflora and vaginal 
pH at physiological levels (acid pH) 
playing a part in the inhibition of 
pathogen growth, and also aids in 
replacing the vaginal ecosystem when 
modified after antibiotic/antimycotic 
treatment. 
Conditions of use 
This health claim is destined for the female population, due to the product's specific vaginal use 
The advised condition of use of this constituent is of at least 1x10
8 ufc per day. 
Since this product's release on the market, there have not been any reported cases of undesirable side effects due to this nutrient, however, italian national law 
imposes the use of these precautions on the product label: Do not exceed the indicated dosage; Keep out of reach of children under three years of age; The 
intake of this supplement is not meant as a substitute to a balanced diet and healthy lifestyle; This product does not substitute antibiotic or chemiotherapeutic 
therapy. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water or warm milk, and drink immediately. Should be consumed, 
preferably, on an empty stomach. 
2958  Food or Food constituent  Health Relationship  Proposed wording 
  Lactobacillus gasseri 
BCCM/LMG P-18137 
Is a probiotic;  
Contributes to a healthy digestive system by supporting the gut flora through an 
increased number of positive lactobacillus in the intestine;  
useful to maintain a healthy intestinal flora by adhering to the mucosa;  
Improves intestinal barrier function by competing (steric encumbrance) against 
pathogens;  
Reduces gastro-intestinal discomfort; Necessary to maintain a healthy digestive 
system by production of specific enzymes (eg: beta-galactosidase).  
Is a probiotic that maintains the balance 
of healthy intestinal microflora and 
regulates intestinal functionality by 
replacing normal, natural microflora 
(especially after antibiotic/antimycotic 
treatment) which contributes to 
reducing gastro-intestinal discomfort 
which, for example, could be due to 
problems in lactose digestion.  
Conditions of use 
Being 'Generally Recognized as Safe' (GRAS) by the Food and Drug Administration, this health claim is destined for the general population. Health claims related to various microorganisms (further assessment) 
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The advised condition of use of this constituent is of at least 1x10
8 ufc per day. 
Since this product's release on the market, there have not been any reported cases of undesirable side effects due to this nutrient, however, italian national law 
imposes the use of these precautions on the product label: Do not exceed the indicated dosage; Keep out of reach of children under three years of age; The 
intake of this supplement is not meant as a substitute to a balanced diet and healthy lifestyle. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water or warm milk, and drink immediately. Should be consumed, 
preferably, on an empty stomach. 
2960  Food or Food constituent  Health Relationship  Proposed wording 
  Lactobacillus paracasei 
CNCM I-1687 
Supports your natural (immune) defence system by increasing the IL-10 
production and enhancing NK cell activity in peripheral blood mononuclear cells 
(PBMC);  
Necessary to maintain the natural defences/helps to maintain a balanced immune 
system (increasing the IL-10 production and enhancing NK cell activity). 
Is a probiotic that helps to support 
body‟s natural defence by modulating 
and regulating the immune response 
(especially in subjects prone to 
inflammatory reactions), which aids in 
supporting the development of the 
immune system. 
Conditions of use 
Being 'Generally Recognized as Safe' (GRAS) by the Food and Drug Administration, this health claim is destined for the general population. 
The advised condition of use of this constituent is of at least 1x10
9 ufc per day. 
Since this product's release on the market, there have not been any reported cases of undesirable side effects due to this nutrient, however, italian national law 
imposes the use of these precautions on the product label: Do not exceed the indicated dosage; Keep out of reach of children under three years of age; The 
intake of this supplement is not meant as a substitute to a balanced diet and healthy lifestyle. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water or warm milk, and drink immediately. Should be consumed, 
preferably, on an empty stomach. 
2961  Food or Food constituent  Health Relationship  Proposed wording 
  Lactobacillus paracasei 
CNCM I-1687 
Is a probiotic;  
Contributes to a healthy digestive system by supporting the gut flora through an 
increased number of positive lactobacillus in the intestine;  
useful to maintain a healthy intestinal flora by adhering to the mucosa;  
Improves intestinal barrier function by competing (steric encumbrance) against 
pathogens;  
Is a probiotic that maintains the balance 
of healthy intestinal microflora and 
regulates intestinal functionality by 
replacing normal, natural microflora 
(especially after antibiotic/antimycotic 
treatment) which contributes to 
reducing gastro-intestinal discomfort 
which, for example, could be due to Health claims related to various microorganisms (further assessment) 
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Reduces gastro-intestinal discomfort;  
Necessary to maintain a healthy digestive system by production of specific 
enzymes (eg: betagalactosidase). 
problems in lactose digestion. 
Conditions of use 
Being 'Generally Recognized as Safe' (GRAS) by the Food and Drug Administration, this health claim is destined for the general population. 
The advised condition of use of this constituent is of at least 1x10
9 ufc per day. 
Since this product's release on the market, there have not been any reported cases of undesirable side effects due to this nutrient, however, italian national law 
imposes the use of these precautions on the product label: Do not exceed the indicated dosage; Keep out of reach of children under three years of age; The 
intake of this supplement is not meant as a substitute to a balanced diet and healthy lifestyle. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water or warm milk, and drink immediately. Should be consumed, 
preferably, on an empty stomach. 
2962  Food or Food constituent  Health Relationship  Proposed wording 
  Lactobacillus paracasei 
CNCM I-1688 
Supports your natural (immune) defence system by increasing the IL-10 
production in peripheral blood mononuclear cells (PBMC);  
As recommended by PASSCLAIM, the functional capacity of the immune system 
has been assessed by: 
- measuring specific cell functions ex vivo   
- measuring specific cell function in vivo e.g. production of cytokines or response 
to antigens and determining the incidence and severity of infection;  
Necessary to maintain the natural defences/helps to maintain a balanced immune 
system (increasing the IL-10 production) 
A probiotic that helps to support the 
body‟s natural defence by modulating 
and regulating the immune response 
(especially in subjects proned to 
inflammatory reactions), which aids in 
supporting the development of the 
immune system 
Conditions of use 
Being 'Generally Recognized as Safe' (GRAS) by the Food and Drug Administration, this health claim is destined for the general population. 
The advised condition of use of this constituent is of at least 1x10
10 ufc per day. 
Since this product's release on the market, there have not been any reported cases of undesirable side effects due to this nutrient, however, italian national law 
imposes the use of these precautions on the product label: Do not exceed the indicated dosage; Keep out of reach of children under three years of age; The 
intake of this supplement is not meant as a substitute to a balanced diet and healthy lifestyle. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water or warm milk, and drink immediately. Should be consumed, 
preferably, on an empty stomach. Health claims related to various microorganisms (further assessment) 
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2963  Food or Food constituent  Health Relationship  Proposed wording 
  Lactobacillus paracasei 
CNCM I-1688 
Is a probiotic;  
Contributes to a healthy digestive system by supporting the gut flora through an 
increased number of positive lactobacillus in the intestine;  
useful to maintain a healthy intestinal flora by adhering to the mucosa;  
Improves intestinal barrier function by competing (steric encumbrance) against 
pathogens;  
Reduces gastro-intestinal discomfort;  
Necessary to maintain a healthy digestive system by production of specific 
enzymes (eg: betagalactosidase). 
Is a probiotic that maintains the balance 
of healthy intestinal microflora and 
regulates intestinal functionality by 
replacing normal, natural microflora 
(especially after antibiotic/antimycotic 
treatment) which contributes to 
reducing gastro-intestinal discomfort 
which, for example, could be due to 
problems in lactose digestion. 
Conditions of use 
Being 'Generally Recognized as Safe' (GRAS) by the Food and Drug Administration, this health claim is destined for the general population. 
The advised condition of use of this constituent is of at least 1x10
9 ufc per day. 
Since this product's release on the market, there have not been any reported cases of undesirable side effects due to this nutrient, however, italian national law 
imposes the use of these precautions on the product label: Do not exceed the indicated dosage; Keep out of reach of children under three years of age; The 
intake of this supplement is not meant as a substitute to a balanced diet and healthy lifestyle. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water or warm milk, and drink immediately. Should be consumed, 
preferably, on an empty stomach. 
2966  Food or Food constituent  Health Relationship  Proposed wording 
  Lactobacillus plantarum 
BCCM/LMG P-17630 
 
Is a probiotic;  
Contributes to a healthy digestive system by supporting the gut flora through an 
increased number of positive lactobacillus in the intestine; 
useful to maintain a healthy intestinal flora by adhering to the mucosa;  
Improves intestinal barrier function by competing (steric encumbrance) against 
pathogens;  
Reduces gastro-intestinal discomfort;  
Necessary to maintain a healthy digestive system by production of specific 
enzymes (eg: betagalactosidase). 
Is a probiotic that defends intestinal 
ecosystem inhibiting the growth of 
pathogenic microorganisms or 
contributes to reducing gastro-intestinal 
discomfort; Replaces natural intestinal 
microflora after antibiotics/antimycotic 
treatment; Influences positively well-
being of body; Is useful for lactose 
digestion.  Health claims related to various microorganisms (further assessment) 
 
31  EFSA Journal 2012;10(8):2858 
Conditions of use 
Being 'Generally Recognized as Safe' (GRAS) by the Food and Drug Administration, this health claim is destined for the general population. 
The advised condition of use of this constituent is of at least 1x10
8 ufc per day. 
Since this product's release on the market, there have not been any reported cases of undesirable side effects due to this nutrient, however, italian national law 
imposes the use of these precautions on the product label: Do not exceed the indicated dosage; Keep out of reach of children under three years of age; The 
intake of this supplement is not meant as a substitute to a balanced diet and healthy lifestyle. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water or warm milk, and drink immediately. Should be consumed, 
preferably, on an empty stomach. 
2967  Food or Food constituent  Health Relationship  Proposed wording 
  Lactobacillus  plantarum 
BCCM/LMG P-17630 
Helps in maintaining balanced vaginal flora and pH;  
Contributes to a healthy colonization of the lactobacilli on the vagina;  
Helps to redress the healthy balanced vaginal microflora during and after treatment 
of vaginal disorders. 
Is a probiotic that helps to maintain 
normal vaginal microflora and vaginal 
pH at physiological levels (acid pH) 
playing a part in the inhibition of 
pathogen growth, and also aids in 
replacing the vaginal ecosystem when 
modified after antibiotic/antimycotic 
treatment.  
Conditions of use 
This health claim is destined for the female population, due to the product's specific vaginal use. 
The advised condition of use of this constituent is of at least 1x10
8 ufc per day. 
Since this product's release on the market, there have not been any reported cases of undesirable side effects due to this nutrient, however, italian national law 
imposes the use of these precautions on the product label: Do not exceed the indicated dosage; Keep out of reach of children under three years of age; The 
intake of this supplement is not meant as a substitute to a balanced diet and healthy lifestyle; This product does not substitute antibiotic or chemiotherapeutic 
therapy. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water or warm milk, and drink immediately. Should be consumed, 
preferably, on an empty stomach. 
2970  Food or Food constituent  Health Relationship  Proposed wording 
  Lactobacillus salivarius 
CNCM I-1794 
Is a probiotic;  
Contributes to a healthy digestive system by supporting the gut flora through an 
Is a probiotic that maintain the balance 
of healthy intestinal microflora and 
regulates intestinal functionality by Health claims related to various microorganisms (further assessment) 
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increased number of positive lactobacillus in the intestine;   
Useful to mantain an healthy intestinal flora adhering to the mucosa;  
Improves intestinal barrier function by competion (steric encumbrance) against 
pathogens;  
Reduces gastro-intestinal discomfort;  
Necessary to maintain a healthy digestive system by production of specific 
enzymes (eg: betagalactosidase). 
replacing normal, natural microflora 
(especially after antibiotic/antimycotic 
treatment) which contributes to 
reducing gastro-intestinal discomfort 
which, for example, could be due to 
problems in lactose digestion. 
Conditions of use 
Being 'Generally Recognized as Safe' (GRAS) by the Food and Drug Administration, this health claim is destined for the general population. 
The advised condition of use of this constituent is of at least 1x10
8 ufc per day. 
Since this product's release on the market, there have not been any reported cases of undesirable side effects due to this nutrient, however, italian national law 
imposes the use of these precautions on the product label: Do not exceed the indicated dosage; Keep out of reach of children under three years of age; The 
intake of this supplement is not meant as a substitute to a balanced diet and healthy lifestyle. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water or warm milk, and drink immediately. Should be consumed, 
preferably, on an empty stomach. 
2971  Food or Food constituent  Health Relationship  Proposed wording 
  Lactobacillus salivarius 
CNCM I-1794 
Supports your natural (immune) defence system by increasing the IL-10 
production in peripheral blood mononuclear cells (PBMC);  
As recommended by PASSCLAIM, the functional capacity of the immune system 
has been assessed by: measuring specific cell functions ex vivo, measuring specific 
cell function in vivo e.g. production of cytokines or response to antigens, and 
determining the incidence and severity of infection;  
Necessary to maintain the natural defences/helps to maintain a balanced immune 
system (increasing the IL-10 production). 
Is a probiotic that helps to support 
natural defences by modulating natural 
immunological responses, and helps to 
support the development of the immune 
system by regulating an immunological 
response in subjects with allergic 
reactions or by stimulating 
immunological response during viral 
infections. 
Conditions of use 
Being 'Generally Recognized as Safe' (GRAS) by the Food and Drug Administration, this health claim is destined for the general population. 
The advised condition of use of this constituent is of at least 1x10
8 ufc per day. 
Since this product's release on the market, there have not been any reported cases of undesirable side effects due to this nutrient, however, italian national law 
imposes the use of these precautions on the product label: Do not exceed the indicated dosage; Keep out of reach of children under three years of age; The Health claims related to various microorganisms (further assessment) 
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intake of this supplement is not meant as a substitute to a balanced diet and healthy lifestyle. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water or warm milk, and drink immediately. Should be consumed, 
preferably, on an empty stomach.  
4231  Food or Food constituent  Health Relationship  Proposed wording 
  Bifidobacterium animalis 
ssp. lactis Bf-6 and 
Lactobacillus johnsonii 
La-1 (ACD-1)(CLbA22) 
NOT GIVEN  NOT GIVEN 
Conditions of use 
NOT GIVEN 
 Health claims related to various microorganisms (further assessment) 
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GLOSSARY AND ABBREVIATIONS 
AFLP      Amplified fragment length polymorphism 
ARDRA    Amplified rDNA restriction analysis 
BCCM/LMG  Belgian  Co-ordinated  Collections  of  Microorganisms/Laboratorium  voor 
Microbiologie, Universiteit Gent 
BV      Bacterial vaginosis 
CNCM     Collection Nationale de Cultures de Microorganismes, France 
DNA      Deoxyribonucleic acid  
IL      Interleukin 
NK cells    Natural killer cells 
PAGE      Polyacrylamide gel electrophoresis 
PBMC      Peripheral blood mononuclear cells 
PCR      Polymerase chain reaction 
PFGE      Pulsed field gel electrophoresis 
RAPD      Randomly amplified polymorphic DNA 
Rep-PCR    Repetitive extragenomic palindromic – PCR 
RNA      Ribonucleic acid  